Antares Pharma, Inc. (Amex:AIS) announced receipt of Notice of Allowance from the United States Patent & Trademark Office (USPTO) covering semi-solid pharmaceutical compositions used in its Advanced Transdermal Delivery (ATD™) technology. The USPTO has stated that it intends to grant patent protection which covers hormonal and non-hormonal formulations developed by Antares Pharma. The patent is expected to issue mid-year and will remain in force until 2021.
This new patent may also provide Antares Pharma with the necessary protection in the field of non-occlusive transdermal delivery of non-hormonal drug products. Anturol™, Antares’ principal ATD product for the treatment of overactive bladder, should also benefit from this additional patent protection. Other targeted therapeutic fields to expand the use of our ATD technology could include anxiety, depression and hypertension.
Jack Stover, President & CEO, of Antares stated, "We believe this patent protection will be an important milestone in Antares’ strategy of strengthening Anturol’s proprietary positioning as well as further expanding the breadth of applications offered by our ATD technology in commercially meaningful ways."
This Notice of Allowance comes shortly after another Notice of Allowance was issued by the USPTO protecting the proprietary formulation used in Antares’ ELESTRIN™ product, an estradiol ATD gel which was co-invented by Antares and its licensee, BioSante.
About Antares Pharma
Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable device engineering capabilities. Antares’ current technology platforms include its ATD™ Advanced Transdermal Delivery system and its EASY TEC™ oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex™ disposable mini-needle injection device and VALEO™/VISION® reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares’ product pipeline, if approved, will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience.
Safe Harbor Statement
In addition to historical facts or statements or current conditions, this press release contains forward-looking statements within the meaning of the “Safe Harbor” provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding notice of allowance and patent issuance and its effect on Antares. Forward-looking statements provide Antares’ current expectation or forecasts of future events. Antares’ results could differ materially from those reflected in these forward-looking statements due to decisions of regulatory authorities, Antares’ ability to execute on its development plans and general financial, economic, regulatory and political conditions affecting the pharmaceutical industry generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in Antares’ quarterly reports filed with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Antares undertakes no obligation to update publicly any forward-looking statement.
